Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Instinct Bio Technical Company Holdings Inc. - Common stock (NQ:BIOT)

0.4294 -0.0106 (-2.41%)
Streaming Delayed Price Updated: 10:57 AM EDT, Aug 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 239,448
Open 0.4300
Bid (Size) 0.4238 (1,200)
Ask (Size) 0.4350 (200)
Prev. Close 0.4400
Today's Range 0.4100 - 0.4550
52wk Range 0.3860 - 50.00
Shares Outstanding 8,024,092
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Instinct Bio Announces Strategic Collaboration With INVITRX to Expand GENREVER Into U.S. and Advance Indonesia Regenerative Medicine Initiatives
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Blade Therapeutics to Participate in “Drug Development in Pulmonary Medicine” Panel Discussion at 2022 BTIG Biotechnology Conference
From Blade Therapeutics, Inc.
Via Business Wire

Performance

YTD
-97.2%
-97.2%
1 Month
-97.2%
-97.2%
3 Month
-97.2%
-97.2%
6 Month
-97.2%
-97.2%
1 Year
-97.2%
-97.2%

More News

Read More
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
Via InvestorPlace
News headline image
Blade Therapeutics Presents Preclinical Data Highlighting Differentiating Characteristics of Cudetaxestat at the American Thoracic Society 2022 International Conference
From Blade Therapeutics, Inc.
Via Business Wire
News headline image
Blade Therapeutics Presents Data from Phase 1 and Preclinical Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference
From Blade Therapeutics, Inc.
Via Business Wire
News headline image
Blade Therapeutics Announces Feedback from FDA on End-of-Phase 1 Data Package
From Blade Therapeutics, Inc.
Via Business Wire
News headline image
Blade Therapeutics to Present Data from Preclinical and Phase 1 Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference
From Blade Therapeutics, Inc.
Via Business Wire
News headline image
Blade Therapeutics Announces Successful Completion of Phase 1 Clinical Study that Evaluated Co-Administration of Cudetaxestat with Either of Two Approved Therapies for Idiopathic Pulmonary Fibrosis
From Blade Therapeutics, Inc.
Via Business Wire

Frequently Asked Questions

Is Instinct Bio Technical Company Holdings Inc. - Common stock publicly traded?
Yes, Instinct Bio Technical Company Holdings Inc. - Common stock is publicly traded.
What exchange does Instinct Bio Technical Company Holdings Inc. - Common stock trade on?
Instinct Bio Technical Company Holdings Inc. - Common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Instinct Bio Technical Company Holdings Inc. - Common stock?
The ticker symbol for Instinct Bio Technical Company Holdings Inc. - Common stock is BIOT on the Nasdaq Stock Market
What is the current price of Instinct Bio Technical Company Holdings Inc. - Common stock?
The current price of Instinct Bio Technical Company Holdings Inc. - Common stock is 0.4294
When was Instinct Bio Technical Company Holdings Inc. - Common stock last traded?
The last trade of Instinct Bio Technical Company Holdings Inc. - Common stock was at 08/04/26 10:57 AM ET
What is the market capitalization of Instinct Bio Technical Company Holdings Inc. - Common stock?
The market capitalization of Instinct Bio Technical Company Holdings Inc. - Common stock is 3.45M
How many shares of Instinct Bio Technical Company Holdings Inc. - Common stock are outstanding?
Instinct Bio Technical Company Holdings Inc. - Common stock has 3M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.